Topic: healthcare

Zealand Pharma (ZEAL) Shares Plunge 23% Following Safety Concerns Over Survodutide Data

06/08/2026, 12:35 PM business stock_drop healthcare
Zealand Pharma's shares fell sharply by 22.7% following concerns over the safety profile of its weight loss drug survodutide, which showed a high dropout rate due to gastrointestinal side effects in a late-stage study. This decline highlights the challenges the company faces in a competitive market dominated by established players like Novo Nordisk and Eli Lilly.

Analysts Bank of America and Goldman Sachs recommend buying Nvidia (NVDA) and Sotera Health (SHC) respectively, while JPMorgan upgrades Tesla (TSLA) to neutral

Recent analyst calls highlight significant shifts in ratings and price targets for various companies, indicating potential investment opportunities and risks for investors. Notably, firms like JPMorgan and Goldman Sachs are optimistic about companies like Qualcomm and Tesla, while others like BTIG and Berenberg express caution on Lululemon and CrowdStrike.